Previous close | 7.05 |
Open | 7.03 |
Bid | 7.71 x 100 |
Ask | 8.03 x 200 |
Day's range | 6.94 - 7.98 |
52-week range | 0.66 - 11.40 |
Volume | |
Avg. volume | 5,513,383 |
Market cap | 234.193M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that they collectively...
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.